(NASDAQ: BOLD) Boundless Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Boundless Bio's earnings in 2026 is -$61,760,000.On average, 5 Wall Street analysts forecast BOLD's earnings for 2026 to be -$48,026,090, with the lowest BOLD earnings forecast at -$55,064,126, and the highest BOLD earnings forecast at -$42,543,854.
In 2027, BOLD is forecast to generate -$23,442,212 in earnings, with the lowest earnings forecast at -$27,641,752 and the highest earnings forecast at -$17,158,571.